New shot aims to help kids with rare heart-muscle disease move easier

NCT ID NCT07531251

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a daily injection called elamipretide in 48 people with genetically confirmed Barth syndrome, a rare condition that causes muscle weakness and heart problems. Participants will receive either the drug or a placebo for 72 weeks. The main goal is to see if the drug improves walking, standing up, and moving around.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BARTH SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Barth syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Bristol Royal Hospital for Children Upper Maudlin Street Paul O'Gorman Building

    Bristol, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Trial Not Offered in the U.S

    Needham, Massachusetts, 02494, United States